
PTO/SB/21 (08-00)

Pill The Control of t			Applica	ation Number	10/078	,949
TRANSMITTAL		Filing I	Date	Februa	ary 20, 2002	
TRANSN FOR	RM		First N	amed Inventor	Stanle	y T. Crooke
be used for all correspon	ndence after ir	nitial filing)	Group	Art Unit	To Be	Determined
<b>?</b>			Examin	er Name	To Be	Determined
Total Number of Pages in Th	is Submission		Attorne	y Docket Number	ISIS00	02-103 (ISIS-5027)
		ENCLO	OSURES (	(check all that apply)		
Fee Transmittal Form			ment Pape Application)		After Grou	Allowance Communication to
Fee Attached		☐ Drawin	g(s)			eal Communication to Board of eals and Interferences
Amendment / Response	•	Licensi	ing-related	l Papers		eal Communication to Group (Ap e, Brief, Reply Brief)
After Final		Petition	า		Prop	rietary Information
Affidavits/declaratio	n(s)		n to Conve ional Appli		☐ Statu	us Letter
			y, Revocation spondence Address		er Enclosure(s) se identify below):	
Express Abandonment	Request	I <u> </u>	inal Disclaimer		PT	m PTO/SB/08a and Form D/SB/08b;
Supplemental Information			st for Refu umber of C	ond CD(s)	Inte Aug	py of (3) Cited References; an ernational Search Report Date gust 23, 2004 for International plication No. PCT/US03/09808
Certified Copy of Priority	<b>y</b>	Rema	rks		Api	Silvation No. P C 17 0 3 0 3 10 3 0 0 0
Response to Missing Pa	arts/		,			
Response to Missin Parts under 37 CFF 1.52 or 1.53						
	SIGNA	TURE OF	APPLIC <i>A</i>	NT, ATTORNEY,	OR AGEN	T
Firm or Paul Individual name	K. Legaard, F	Ph.D., Regist	ration No.	38,534		
Signature RPC P						
Date EURTEMSON 19, 2004						
		CE	RTIFICA	TE OF MAILING		
I hereby certify that this cor addressed to: Commission		=				e as first class mail in an envelo te:
Typed or printed name		<del></del>		n No. 38,534		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Crooke

Serial No.: 10/078,949

Group Art Unit: To Be Determined

Filing Date: February 20, 2002

Examiner: To Be Determined

For: Oligoribonucleotides And Ribonucleases For Cleaving RNA

I certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313-1450.

on 19 SOFTEMBOR 20:44

Paul K. Legaard, Ph.D., Registration No. 38,534

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Ir	nforma	tion Disclosure Statement is being filed:				
	within	three months of the filing date of the patent application.				
		three months of the date of entry into the national stage as set forth in F.R. § 1.491 of the international application.				
$\boxtimes$	before the mailing date of a first Office Action on the merits.					
	mailin	the mailing date of a first Office Action on the merits, but before the g date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of ance under 37 C.F.R. § 1.311, and accordingly is accompanied by:				
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);				
		or				
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or				
	$\boxtimes$	No fee is owed by the applicant(s).				
	In acc	ordance with 37 C.F.R. § 1.129(a), this Information Disclosure				
	Statement is being filed in connection with  the first or second After					
	Final Submission, and accordingly is accompanied by the Statement under 37					
		. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.				
	after t	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a				
	Notice	e of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously				
	with, the payment of the Issue Fee, and accordingly is accompanied by the					
	Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the					
	Information Disclosure Statement and the Petition Fee of \$130.00 set forth in					
	37 C.I	F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).				
$\boxtimes$	A cop	y of the references listed on the attached PTO Form SB/08a and PTO				
	Form	SB/08b, formerly known as PTO Form 1449 is enclosed. Also enclosed				
	is a copy of the International Search Report Dated August 23, 2004 for					
	Intern	ational Application No. PCT/US03/09808.				

]	EXCI	EPT TI	HAT:
			In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
			In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
			If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
:	State	ment u	nder 37 C.F.R. § 1.97(e)
l		in the	Information Disclosure Statement was cited in a communication from a gn patent office in a counterpart foreign patent application not more than months prior to the filing of the Information Disclosure Statement.
j	Fees		÷
	$\boxtimes$	No Fe	ee is owed by the applicant(s).
			Information Disclosure Statement Fee of \$180.00 under 37 C.F.R.

The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Metho	od of Payment of Fees
	Attached is a check in the amount of \$ This form is
	submitted in duplicate.
	Charge Deposit Account No. 50-1275 in the amount of \$ This form is
	submitted in duplicate.
$\boxtimes$	Please charge any deficiency or credit any overpayment to Deposit Account
	50-1275.
	No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Paul K. Legaard, Ph.D. Registration No. 38,534

Dated: 14 Seprember 2004

COZEN O'CONNOR, P.C. 1900 Market Street, 5<sup>th</sup> Floor Philadelphia, PA 19103-3508 (215) 665-2000 – Telephone (215) 701-2013 - Facsimile

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

t of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 144

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known				
Application Number	10/078,949			
Filing Date	February 20, 2002			
First Named Inventor	Stanley T. Crooke			
Group Art Unit	To Be Determined			
Examiner Name	To Be Determined			
Attorney Docket Number	ISIS0002-103 (ISIS-5027)			

			U.S. PATENT	OCUMENTS		
Examiner	Cito	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials *	Cite No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	Gυ	US-6,107,094	08/22/2000	Crooke		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	l	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS					
	a	Foreign Patent Document	- 4.0	Name of Patentee or	Pages, Columns, Lines,	
Examiner Cite Initials* No.1		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
					-	
	<del></del>					

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional) . <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under to Reperwork Reduction of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449 ATTANDER

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Complete if Known

Application Number 10/078,949

Filing Date February 20, 2002

First Named Inventor Stanley T. Crooke

Group Art Unit To Be Determined

Examiner Name To Be Determined

Attorney Docket Number ISIS0002-103 (ISIS-5027)

(use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket Number ISIS0002-103 (ISIS-5027)

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	GV	Struck, "Vaccine R&D Success Rates And Development Times," <i>Nature Biotechnology</i> , May 1996, Vol. 14, pp. 591-593.	
	GW	Ohtsuka et al., "Recognition By Restriction Endonuclease <i>Eco</i> RI Of Deoxyoctanucleotides Containing Modified Sugar Moieties," <i>J. Biochem</i> , 1984, Vol. 139, pp. 447-450.	
	GX	International Search Report Dated August 23, 2004 for International Application No. PCT/US03/09808.	
1			
-			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.